aspect biosystems clinical trial:Aspect wins $72.75m from Canadian government for ...
Aspect wins $72.75m from Canadian government for ...
2024年7月11日—CanadianbiotechAspectBiosystemshasreceiveda$72.75mgovernmentinvestmenttoadvanceitsproprietarybioprintingtechnology.。其他文章還包含有:「AspectBiosystemsEntersCollaborationwithMcMaster...」、「AspectBiosystems」、「GovernmentsofCanadaandBritishColumbiajoinforces...」、「AspectBiosystemsAnnounces$200MillionPartnership...」、「3Dprintinglivingtissuetotreatdiabetesisclosertoclinical...
查看更多 離開網站Aspect Biosystems Enters Collaboration with McMaster ...
https://www.aspectbiosystems.c
RX1 3D Bioprinter will be used to investigate novel disease mechanisms to enable the discovery of therapies for patients with chronic lung ...
Aspect Biosystems
https://www.aspectbiosystems.c
Our transformative platform technology combines our proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design.
Governments of Canada and British Columbia join forces ...
https://www.canada.ca
$200 million project will enable manufacturing of cutting-edge bioprinted tissue therapeutics and advance a global leading technology platform in Canada.
Aspect Biosystems Announces $200 Million Partnership ...
https://lifesciencesbc.ca
Aspect Biosystems announced that it has received a $72.75 million investment from the Governments of Canada and British Columbia.
3D printing living tissue to treat diabetes is closer to clinical trials
https://vet.ucalgary.ca
Aspect Biosystem is working to advance its bioprinted therapeutic program towards clinical evaluation and, “ultimately, introducing a ...
Aspect Biosystems and Novo Nordisk enter partnership to ...
https://www.novonordisk.ca
The collaboration will initially focus on developing bioprinted tissue therapeutics designed to maintain normal blood glucose levels without the ...
Aspect Biosystems
https://radical.vc
Aspect Biosystems is building a new class of regenerative medicine with a full-stack tissue therapeutic platform.
Breakthrough T1D Collaboration Leads to Next
https://www.breakthrought1d.or
Aspect Biosystems and Novo Nordisk announced a partnership to expand the development a new class of treatments for diabetes and obesity.